EGFR and neoplasm: This ADC contrasts with other conjugates with moderate or unknown mAb biological activity, such as D2B–duocarmycin, intended for prostate cancer, and CyEt-Pan-Duo, targeting EGFR, showing no tumor growth inhibition and growth inhibition without tumor-shrinking, respectively [104,105].